Introduction: Obligatory symptoms of IBS are abdominal pain and discomfort and alterations of defecation habits during at least 3 of the previous 12 months.
Aim of study was to evaluate the effectiveness and capsules in irritable bowel syndrome (IBS) and the tolerability of Meteospasmyl.
Patients and method: The study was open, self-controlled, multicentre, phase IV study lasting for 2,5 months with 2 weeks follow-up, involving 186 patients suffering from IBS.
The study covers the effect of the product on patients' complaints during the therapy as well as the changes in the complaints in the weeks following the therapy. The study period is 2,5 months, during which time the patient is examined 5 times, on days –15, 0, 14, 28 and 60. The daily dose was 3×1 capsules. After 4 weeks treatment is ceased, during the 1 month period capsule. Between visits 4 and 5 the patients did not get Meteospasmyl. During the study the physician evaluated the symptoms and scores them according to the patients' description during the visits (days 0, 14, 28 and 60)
Results: There were significant differences in a four tested parameters (general well being, abdominal pain, flatulence and defecation): The well-being significantly improves, the intensity of abdominal pain and the intensity of flatulence decreased significantly, defecation improved significantly.
Conclusion: The Meteospasmyl therapy is effective and safe for the treatment of IBS.
